We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+18.81%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$457M
AUM Growth
+$11.9M
Cap. Flow
+$29.8M
Cap. Flow %
6.53%
Top 10 Hldgs %
47.78%
Holding
85
New
14
Increased
34
Reduced
11
Closed
24

Top Buys

Rank Stock Value
1
PLRX icon
Pliant Therapeutics
PLRX
+$18M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$14.6M
3
VRNA
Verona Pharma
VRNA
+$6.28M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$6.17M
5
ASND icon
Ascendis Pharma A/S
ASND
+$6.11M

Top Sells

Rank Stock Value
1
PSTX
Poseida Therapeutics, Inc. Common Stock
PSTX
+$14M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$9.84M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$6.6M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$6.4M
5
ADCT icon
ADC Therapeutics
ADCT
+$5.65M

Sector Composition

Rank Sector Weight
1 Healthcare 97.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BDSX icon
26
Biodesix
BDSX
$211M
$6.63M 1.45%
216,614
+38,559
+22% +$1.13M
AKRO
27
CALL
DELISTED
Akero Therapeutics
AKRO
$6.12M 1.34%
+220,000
New +$6.66M
GOSS icon
28
Gossamer Bio
GOSS
$101M
$5.58M 1.22%
6,171,847
+526,495
+9% +$451K
PRAX icon
29
Praxis Precision Medicines
PRAX
$8.11B
$5.58M 1.22%
72,516
+5,471
+8% +$396K
BBOT
30
BridgeBio Oncology
BBOT
$660M
$5.39M 1.18%
513,369
– –
RARE icon
31
Ultragenyx Pharmaceutical
RARE
$2.46B
$5.23M 1.14%
+124,388
New +$6.17M
KALV
32
DELISTED
KalVista Pharmaceuticals
KALV
$5.19M 1.13%
612,173
+37,615
+7% +$390K
TVTX icon
33
Travere Therapeutics
TVTX
$5.17B
$4.83M 1.06%
+277,365
New +$4.91M
CCCC icon
34
C4 Therapeutics
CCCC
$389M
$4.4M 0.96%
1,221,131
+73,240
+6% +$364K
GPCR icon
35
Structure Therapeutics
GPCR
$3.37B
$4.13M 0.9%
152,395
+81,879
+116% +$2.91M
TARS icon
36
Tarsus Pharmaceuticals
TARS
$2.55B
$3.65M 0.8%
65,955
+25,955
+65% +$1.18M
INCY icon
37
Incyte
INCY
$25.8B
$3.38M 0.74%
+49,000
New +$3.49M
PCVX icon
38
Vaxcyte
PCVX
$7.65B
$3.34M 0.73%
40,788
-19,712
-33% -$1.96M
GERN icon
39
Geron
GERN
$898M
$3.26M 0.71%
920,022
-881,539
-49% -$3.52M
TRVI icon
40
Trevi Therapeutics
TRVI
$2.57B
$3.03M 0.66%
734,234
+251,659
+52% +$806K
CGEN icon
41
Compugen
CGEN
$212M
$2.49M 0.54%
1,624,377
+123,264
+8% +$200K
CERS icon
42
Cerus
CERS
$575M
$2.44M 0.53%
1,587,228
+91,899
+6% +$158K
SNDX icon
43
CALL
Syndax Pharmaceuticals
SNDX
$1.7B
$2.28M 0.5%
+172,400
New +$2.95M
ABVX
44
Abivax
ABVX
$10.4B
$2.09M 0.46%
285,120
-176,540
-38% -$1.63M
UNCY icon
45
Unicycive Therapeutics
UNCY
$130M
$1.97M 0.43%
248,671
-151,329
-38% -$838K
VRDN icon
46
Viridian Therapeutics
VRDN
$2.2B
$1.92M 0.42%
+100,000
New +$2.17M
DCTH icon
47
Delcath Systems
DCTH
$400M
$1.87M 0.41%
+155,325
New +$1.64M
QURE icon
48
uniQure
QURE
$2.78B
$1.77M 0.39%
+100,000
New +$863K
MODD icon
49
Modular Medical
MODD
$11.3M
$1.74M 0.38%
42,401
-5,599
-12% -$325K
KALA icon
50
KALA BIO
KALA
$12.5M
$1.6M 0.35%
+4,621
New +$1.46M
1
2
3 4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
PE
PSG Equity Boston, Massachusetts $977M AUM 13.39% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM

Silverarc Capital Management's Q4 2024 Portfolio in Review

As of Q4 2024, Silverarc Capital Management held 85 positions worth $457M, up 2.7% from $445M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Silverarc Capital Management deployed $29.8M of net new capital in Q4 2024, opening 14 new positions and adding to 34 existing holdings. Its largest new stake was Pliant Therapeutics: 1,315,601 shares worth $17.3M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Poseida Therapeutics, Inc. Common Stock, an estimated $14M trimmed.

  • Silverarc Capital Management's largest Q4 2024 buy was Pliant Therapeutics: 1,315,601 shares worth $17.3M.
  • Silverarc Capital Management added most to Syndax Pharmaceuticals in Q4 2024, an estimated $14.6M increase.
  • Silverarc Capital Management's biggest Q4 2024 reduction was Poseida Therapeutics, Inc. Common Stock, cutting an estimated $14M.
  • Silverarc Capital Management fully exited Alnylam Pharmaceuticals in Q4 2024, selling an estimated $9.84M.
  • Silverarc Capital Management's ten largest holdings make up 48% of its $457M portfolio in Q4 2024.
  • Silverarc Capital Management opened 14 new positions and closed 24 in Q4 2024.
  • Silverarc Capital Management's portfolio value rose 2.7% quarter-over-quarter to $457M.

Based on Silverarc Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.